The AUA Annual Meeting Provides Invaluable Information

Friday, February 3, 2017

The AUA Annual Meeting Provides Invaluable Information

An accomplished pharmaceutical physician, Dr. Erol Onel serves as a vice president of Heron Therapeutics in California. In this capacity, he provides scientific leadership to the company and attends meetings to develop clinical plans and strategies. Dr. Erol Onel has been a member of several professional organizations over the years, including the American Urological Association (AUA).

Since 1902, the AUA has been using research and education to promote the highest standards of clinical care. One of the organization’s premier educational and networking events is the AUA Annual Meeting. As the world’s largest gathering of urologists, the AUA Annual Meeting provides attendees with access to groundbreaking research, information about advances in neurological medicine, and details about new guidelines pertaining to the field.

The 2017 AUA Annual Meeting will be the event’s 112th. Scheduled from May 12 to 16, the event will be held in Boston and continue the meeting’s legacy of providing invaluable information to attendees. Urologic health care professionals and urologists from around the world are encouraged to attend. This year’s meeting is expected to feature more programming and educational offerings than meetings in the past, and the organization hopes that attendance will exceed the over 16,000 figure for the 2016 meeting.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

About Erol Onel

A physician in New Jersey focused on pharmaceutical development, Erol Onel, MD, most recently served Pacira Pharmaceuticals, Inc., as vice president of clinical research and medical information. In these roles, Dr. Erol Onel’s responsibilities included overseeing studies presented to the US Food and Drug Administration and engaging with Pacira’s regulatory department to ensure the completion and transmission of regulatory documentation. Among his accomplishments at Pacira, he guided the launch and approval of the firm’s major product, a non-opioid pain medication.

Over the course of his career, Dr. Onel has led held leadership roles in all areas of clinical development. With particular experience in male fertility, he played an integral role in the development of degarelix (Firmagon), a drug used in the treatment of prostate cancer.

Dr. Erol Onel earned his doctor of medicine at Yeshiva University’s Albert Einstein College of Medicine and completed a residency in urology at the University of Connecticut Health Center. Subsequently, he fulfilled the obligations of a research fellowship in andrology and sexual dysfunction at the University of Illinois at Chicago.